Immune control by amino acid catabolism during tumorigenesis and therapy by Lemos H et al.
 1 
 
Immune Control by Amino Acid Catabolism During 
Tumourigenesis and Therapy 
Henrique Lemos1, Lei Huang1, George C. Prendergast2 and Andrew L. Mellor1*. 
 
 
*Corresponding author: tel; 0191 208 8503 email; andrew.mellor@ncl.ac.uk 
 
Author affiliations: 1Institute of Cellular Medicine, Faculty of Medical Sciences, Framlington 
Place, Newcastle University, Newcastle-upon-Tyne NE2 4HH. 2Lankenau Institute for Medical 
Research, 100 East Lancaster Avenue, Wynnewood, PA 19096 USA. Ph: 484.476.8400; Fax: 
484.476.8533 
  
 
 
 2 
Abstract:  
Immune checkpoints arise from physiologic changes during tumourigenesis that re-programme 
inflammatory, immunologic and metabolic processes in malignant lesions and local lymphoid 
tissues, which constitute the immunologic tumour microenvironment (TME). Improving clinical 
responses to immune checkpoint blockade will require deeper understanding of factors that 
impact local immune balance in the TME. Elevated catabolism of the amino acids tryptophan 
(Trp) and arginine (Arg) are common TME hallmarks at clinical presentation of cancer. Cells 
catabolising Trp and Arg suppress effector T cells and stabilize regulatory T cells (Tregs) to 
suppress immunity in chronic inflammatory diseases of clinical significance, including cancers. 
Processes that induce Trp and Arg catabolism in the TME remain incompletely defined. 
Indoleamine 2,3 dioxygenase (IDO) and arginase (ARG1), which catabolise Trp and Arg 
respectively, respond to inflammatory cues including interferons (IFNs) and TGFβ cytokines. 
Dying cells generate inflammatory signals including DNA, which is sensed to stimulate the 
production of type I IFNs via the Stimulator of Interferon Genes (STING) adaptor. Thus, dying 
cells help establish local conditions that suppress anti-tumour immunity to promote 
tumourigenesis. Here we review evidence that Trp and Arg catabolism contributes to 
inflammatory processes that promote tumourigenesis, impede immune responses to therapy 
and might promote neurologic comorbidities associated with cancer.  
 
  
 3 
[H1] Introduction   
Loss of cell growth control and increased cell survival are necessary but insufficient 
adaptations that precede malignant tumour formation, as benign pre-malignant lesions develop 
in tissues of many people who do not get cancer 1. In most people, inflammation associated with 
pre-malignant lesions activates local innate immune surveillance mechanisms that prevent 
benign lesions from transitioning into malignant tumours 2. In rare cases, cancer develops 
because local immune regulation becomes dominant, allowing pre-malignant lesions to evade 
immune surveillance and form malignant tumours. Immune evasion occurs early in tumour 
development, in part by activation of immune checkpoints creating robust barriers to anti-tumour 
immunity. How developing tumours evade immune surveillance is poorly understood, as it is 
difficult to detect pre-malignant lesions and determine their impact on local immune processes 
as well as draining lymphoid tissues.  
 At clinical presentation, immune checkpoints are well established and hint at pathways that 
promote immune evasion (Fig. 1). At early stages of tumour development local immune effector 
processes that mediate immune surveillance are overcome progressively by tolerogenic 
(immune regulatory) processes that become dominant in malignant lesions and in tumour-
draining lymph nodes (TDLNs), which together constitute the immunologic tumour 
microenvironment (TME). In essence, the TME is a site of chronic immune activation where 
immunogenic and tolerogenic processes are activated constitutively, reflecting Dvorak’s 1986 
comment that malignancies are “wounds that do not heal”3. Chronic immune activation provides 
growth factors that promote tumour growth and angiogenesis and also suppresses anti-tumour 
immunity. Viewed from this perspective, therapeutic success depends on killing tumour cells, 
skewing local immune balance in favour of sustained dominance of immunogenic processes 
that kill tumour cells faster than they can be replaced and preventing re-emergence of dominant 
tolerogenic processes after therapy ceases. The final point is important because any tumour 
cells surviving initial therapy would benefit from a resurgent tolerogenic TME that nurtures 
tumour re-growth and metastasis. 
In this review, we focus on increased local catabolism of the essential amino acid tryptophan 
(Trp), a common local feature that attenuates anti-tumour immunity in primary tumour lesions 
and TDLNs. Arg catabolism has also been linked to suppression of anti-tumour immunity; 
however, as less is known about Arg catabolism, and as its role in generating bioactive 
polyamines that impact cancer was discussed in a recent review,4 we will only discuss Arg 
briefly here. Amino acid catabolism is thought to reinforce immune checkpoints that suppress 
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adaptive T cell immunity. Consistent with this notion, several drugs that act by different 
mechanisms to inhibit indoleamine 2,3 dioxygenase enzyme activity, which catalyzes the first 
step of Trp catabolism, have yielded encouraging clinical responses in initial Phase II trials 5,6. 
However, the first IDO inhibitor drug to be studied in a Phase III trial did not synergise with 
immune checkpoint inhibition (PD-1 pathway blockade) to improve clinical outcomes in 
melanoma 7, emphasizing the need for more research to understand how amino acid catabolism 
contributes to immune checkpoints that control immune balance during tumour development 
and following therapy.  
[H1] Amino acids and tumour growth 
As protein building blocks amino acids are essential for tumour growth, and for re-modeling 
stromal and vascular architecture in the inflamed TME as tumours develop. Hence, it appears 
counter-intuitive that elevated Trp and Arg catabolism would promote tumour growth. However, 
immune cells also need amino acids to expand and differentiate into effector cells capable of 
killing tumour cells. These considerations highlight the need for deeper understanding of how 
cells sense amino acids and adjust their functions accordingly when access to amino acids is 
limited. Suppressing immunity by catabolizing Trp and Arg might be more important for tumour 
development than constraints on tumour growth due to reduced access to these amino acids. 
Cells could also adapt to compensate for reduced amino acid access, for example by up-
regulating amino acid transporters and tRNA-charging enzymes. Of note, the Trp-tRNA 
charging enzyme (WARS) is uniquely induced by type II interferon (IFNγ), suggesting that 
enhanced access to Trp might help cells survive in inflamed tissues 8. 
[H2] Amino acid catabolism activates cellular stress responses 
Cells sense amino acids via two ribosomal kinases, the eIF2α kinase GCN2 and mTOR. When 
access to amino acids is limiting GCN2 and/or mTOR activate and stimulate radical re-
programming of cell functions, leading to cell cycle arrest and autophagy. GCN2 senses binding 
of uncharged tRNA to ribosomes and shuts down mRNA translation and promotes cell 
autophagy, which releases amino acids and makes cells more resilient to nutrient stress 9. 
GCN2 is required for optimal growth of sarcoma cells in mice and in culture, suggesting that the 
integrated stress response (ISR) driven by activated GCN2 promotes sarcoma growth 10. mTOR 
is also required for optimal tumour growth in many models, though sensing amino acids is only 
one aspect of metabolic control by mTOR 11. Dividing tumour cells must increase amino acid 
transport to make new proteins and several studies identified links between amino acid 
transporters, mTOR activity, metabolic re-programming and tumour growth 12-14. In the mouse 
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DBMA/TPA model of inflammatory skin carcinogenesis and a KRAS-induced model of lung 
tumorigenesis, Ido1 gene expression was required for optimal tumour development 15,16. These 
genetic data reinforced pharmacological evidence that 1-methyl-D-tryptophan (D-1MT) could 
reverse the immune suppressive effects of IDO activity by inhibiting mTOR activation to promote 
cell autophagy via a GCN2-independent mechanism 17,18. Tumour cells might compensate for 
reduced access to amino acids by up-regulating expression of amino acid transporters and by 
modulating their sensitivity to amino acid sensors that activate GCN2 and mTOR signaling. 
Initial indications that Trp catabolism promoted tumour growth emerged from studies in mice 
treated with IDO inhibitors, which slowed growth of subcutaneous Lewis Lung Carcinoma (LLC) 
and B16 melanoma tumour grafts and in autochthonous HER2-induced breast tumours 19-21. In 
the subcutaneous tumour models, tumour cells did not express IDO but tumour formation 
induced sustained elevation of IDO activity in dendritic cells (DCs) located in inflamed TDLNs 22. 
In the HER2 breast tumour model, IDO inhibitors were most potent when combined with DNA-
damaging radio or chemotherapy 20, prompting significant interest in targeting IDO as novel 
approaches to boost clinical responses after these treatments.  
[H1] Inflammation induces IDO1 and ARG1 
Tumour-associated inflammation stimulates Trp and Arg catabolism, with consequences for 
tumour development, therapy and comorbidities associated with some cancers (Fig. 2). 
Increased cell death is a common feature of aseptic inflammation in the TME that generates 
damage-associated molecular patterns (DAMPs), including DNA. Microbial and mitochondrial 
DNAs are sensed by Toll-Like receptor-9 (TLR9), which is expressed by specialized antigen 
presenting cells (APCs) 23. In contrast, many cells express cytosolic DNA sensors such as the 
nucleotidyltransferase cyclic GMP-AMP synthase (cGAS), which activate the adaptor Stimulator 
of Interferon Genes (STING), a potent IFNβ inducer 24. In common with many DAMP sensors, 
DNA sensors like cGAS activate innate immune cells, which express cytokines that can 
stimulate or suppress immunity. Many innate immune cells produce IFNαβ and IFNγ, and IFNs 
in turn stimulate many downstream genes, including genes encoding enzymes that catabolize 
Trp (see below) and genes encoding other cytokines that enhance Arg catabolism such as 
TGFβ 23. 
[H2] Genes encoding enzymes that catabolise tryptophan 
In humans and mice, two unrelated enzymes IDO1 and tryptophan 2,3 dioxygenase (TDO) 
catalyze the initial step of Trp catabolism to generate a series of downstream catabolites, some 
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of which, like kynurenine (Kyn) are secreted. Two isotypic and closely linked genes IDO1 and 
IDO2 encode IDO apoenzymes, which form holoenzymes with haem (tetrapyrrole) cofactors. 
IFNα, IFNβ and IFNγ are potent IDO1 inducers but regulation of IFN signaling restricts IDO1 
expression to particular cell types. IDO2 is largely refractory to IFN signaling but Kyn enhances 
IDO2 transcription and other evidence points to roles for IDO2 in immune cells 25. In contrast, 
TDO gene expression responds to dietary intake in some liver cells and to glucocorticoid stress 
in other cells 26. Increased Trp catabolism in cancer patients might have adverse effects on 
mood and cause depression because Trp is the obligate precursor for synthesis of the 
neurotransmitter serotonin (also known as 5-hydroxytryptamine, 5HT) and the hormone 
melatonin, which regulate mood and depressive behaviours. Moreover, some Trp catabolites 
are neuro-active, including quinolinic (QA), kynurenic (KA) and picolinic acids (PA) 27. Arg is 
catabolized by arginase (ARG1) and nitric oxide synthetase (NOS). Nitric oxide is a vasodilator, 
impacts immune functions and inactivates IDO, as well as other enzymes containing haem 
cofactors 28. The ARG1 product L-ornithine can be converted into polyamines, which regulate 
cell proliferation, and might influence tumour development and tumour immunity 4,29. IFNγ 
stimulates inducible NOS (iNOS) and T helper 2 (Th2) cytokines (IL-4, IL-13) induce ARG, while 
IDO1 and ARG1 genes are both responsive to the immune suppressive cytokine transforming 
growth factor β (TGFβ) 30,31.  
Expression of IDO1 and TDO in tumours are of chief interest for therapeutic targeting, as 
elevated IDO1 and TDO expression manifests in many cancer types 32-35. Our unpublished 
analyses [Lei: OK] of public databases (e.g. kmplot.com & proteinatlas.org) reveal that relatively 
high IDO or TDO expression correlate with poor patient survival in some cancers (e.g. lung, 
acute myeloid leukemia (AML), gastric) but not others (e.g. breast). However, enzyme activity 
was assessed in few studies, a key point as gene expression might not enhance enzyme 
activity 33,35. IDO1 is often overexpressed in tumour cells through genetic and epigenetic 
mechanisms of pathogenic significance, such as RAS oncogene activation, pro-inflammatory 
COX2 activation and BIN1 tumour suppressor inactivation 36. Elevated IDO enzyme activity 
occurs in many human cancers, including those of the esophagus, stomach, pancreas, colon, 
lung, breast, ovary, prostate, bladder, skin, and brain 37-42, though it is not always clear if 
elevated IDO expression occurs in tumour, immune or stromal cells.  IDO1 expression also 
correlated with poor clinical outcomes after therapy in multiple tumour types 39,43,44. Though TDO 
is not expressed in immune cells, TDO elevation in tumour cells, for example human 
glioblastoma cells, might promote immune suppression in the TME that enhances tumour 
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growth 45. TDO elevation could also contribute to pathogenesis by non-immune mechanisms in 
tumours such as breast cancer, where IDO1 expression is typically but not always absent 46,47. 
Some human tumours express both IDO1 and TDO 32 and concerns that tumours might exploit 
TDO as an escape pathway prompted development of drugs that block both enzymes. 
[H1] Trp and Arg catabolism affects T cells  
Access to amino acids is necessary for resting (naïve) T cells to proliferate and differentiate 
into effector cells. After stimulation, T cells rapidly up-regulate an array of amino acid 
transporters, including SLC7A5. Ablating SLC7A5 blocked metabolic re-programming via 
activation of mTOR, and expression of the transcription factor MYC to prevent T cell 
proliferation 48, revealing a critical need for enhanced amino acid access to sustain T cell 
responses after priming. However, T cells have differential requirements for specific amino 
acids, as depletion of Trp or Arg activated GCN2 to block entry into S-phase following T cell 
stimulation, while depletion of both isoleucine (Ile) and leucine (Leu) led to cell cycle entry (S/G1 
transition), though T cells stopped dividing and died soon afterwards 49-51. These distinctive 
responses suggest that T cell access to sufficient Trp and Arg are key signals required for cell 
cycle entry, while restricted access to other amino acids does not block cell cycle entry but 
causes catastrophic nutrient ‘starvation’ soon after cell cycle entry. It may not be a coincidence 
that elevated Trp and Arg catabolism are common TME hallmarks. These adaptations could 
represent an evolved counter-regulatory ‘healing’ response to restrain immune-mediated injury 
in inflamed tissues where immune-activation thresholds are reduced. Malignant lesions might 
hijack tissue healing responses to suppress anti-tumour immunity and create robust immune 
checkpoints. 
Previous reviews describe how elevated Trp and Arg catabolism inhibits adaptive immunity by 
suppressing effector T cells and potentiating FOXP3-lineage regulatory CD4+ T cell (Treg) 
functions 33,35. In brief, tumour or stromal cells in malignant lesions catabolizing Trp and/or Arg 
suppress CD8+ effector T cells and stabilize Treg cells to protect tumour cells. Similarly, in 
TDLNs, APCs catabolizing Trp and Arg suppress expansion of conventional CD4+ helper T 
cells and tumour-specific effector CD8+ T cells and stimulate and stabilize Tregs (Fig. 1). The 
combined actions of Trp and Arg depletion and Trp catabolite production at these discrete TME 
sites create robust barriers to anti-tumour immunity that complement immune checkpoints 
mediated by CTLA4 and PD-1–PD-L1 pathways in T cells. For example, the PD-1 and IDO 
pathways synergized to stabilize Tregs in the B16 mouse melanoma model 52. While PD-1 
signaling maintained PTEN activity to prevent PI3K activation, IDO activity activated GCN2 to 
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block mTOR complex 2 (mTORC2) activation in Tregs. These metabolic pathways synergized 
to suppress AKT signaling, thereby preventing de-stabilization of Treg regulatory functions in 
the inflamed TME. The distinctive roles of PTEN as a tumour suppressor in T-ALL and a Treg 
stabilizer in the B16 melanoma model emphasize that a particular pathway can be active in 
multiple TME cell types and have differential effects on tumour growth or responses to therapy 
in specific models.  
Tregs can undergo re-programming to provide helper or effector immune functions if they 
receive appropriate inflammatory signals. Physiologic factors driving Tregs to adopt diametric 
functions remain poorly defined but are important, as they will provide novel insights on how to 
improve clinical responses in cancer patients by skewing the local immune balance in the TME 
in favour of immunogenic processes that target tumour cells. Since local Trp and Arg catabolism 
activates and stabilizes Treg functions, it follows that inhibiting these metabolic pathways might 
de-stabilize Tregs to weaken a formidable barrier to anti-tumour immunity in the TME. For 
example, Tregs unexpectedly provided ‘helper’ functions to prime effective T cell responses to a 
tumour vaccine in naïve mice but ‘Treg help’ was suppressed via an IDO-dependent mechanism 
in mice with established B16 melanomas 53. Stability might also differ amongst Treg subsets. In 
mice harbouring B16 melanomas, TDLN DCs expressing IDO activated a PD-1+ Treg subset via 
a GCN2-dependent mechanism to stabilize the transcription factor EOS (also known as IKZF4), 
an obligate FOXP3 co-repressor, and prevent Treg re-programming 54,55. Thus, the sensitivity of 
some Tregs to Trp and Arg catabolism reveals potential targets to promote Treg re-
programming, and to weaken immune checkpoints in cancer patients. 
[H1] Catabolism of Trp and Arg in the TME  
T cells and Tregs respond to Trp and Arg catabolism; thus, degradation of these amino acids 
by tumour or accessory cells expressing IDO, TDO and/or ARG regulate T cell immunity in the 
inflamed TME. This scenario, in which interactions between distinct cell types regulate immune 
balance in the TME, mirrors how accessory cells expressing PD-1 ligands regulate T cell 
immunity.  Some, but not all, tumour cells have elevated IDO, TDO, ARG, and iNOS enzyme 
activity, and in some cases resident stromal cells and/or infiltrating immune cells express these 
enzymes to promote Trp and Arg catabolism in the TME.  
[H2] Monocytic cells that catabolize Trp and Arg 
Monocyte-derived cells such as DCs and macrophages are innate immune cells with pivotal 
roles in promoting and regulating adaptive immunity. Due to sustained inflammation in the TME, 
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monocyte-derived cells found in the TME can exhibit distinctive phenotypes that differ from 
circulating peripheral blood monocytes (PBMCs) and APCs found in homeostatic tissues (Fig 1). 
For example, in mice with subcutabeous B16 melanoma or LLC tumour grafts, a discrete DC 
subset with potent T cell regulatory attributes (DCregs) exhibited IDO1 activity in TDLNs and 
displayed features of both B cells and plasmacytoid DCs 22,56. Some DCs generated from 
human PBMCs can also express IDO1 and regulate T cell immunity in response to inflammatory 
signals 57,58. Moreover, elevated numbers of IDO1-expressing DCs were observed in sentinel 
lymph nodes from some melanoma patients 59 consistent with the notion that TDLN DCs 
expressing IDO1 regulate T cell immunity in some cancer patients.  
Myeloid-derived suppressor cells (MDSCs) with macrophage and granulocyte-neutrophil 
attributes infiltrate many primary tumour lesions in humans and mice. MDSCs often express 
ARG, reflecting their potential origin as alternatively activated M2 macrophages 60,61. Some 
MDSCs also exhibit other immune regulatory hallmarks, including IL-10, TGFβ and IDO 16. In 
mice and humans with melanoma, IDO activity in tumour cells promoted MDSC recruitment and 
activation via a Treg-dependent mechanism in the TME 16,62. Accordingly, IDO inhibition 
reduced MDSC and Treg numbers and diminished their regulatory functions. Increased 
numbers of circulating MDSCs expressing ARG1 were also observed in glioblastoma patients 
63. Fibrocytes that expanded and circulated amongst PBMCs in cancer patients also suppressed 
mitogen-activated T cell proliferation ex vivo, primarily via IDO, unlike circulating fibrocytes from 
healthy donors that potentiated T cell proliferation 64. Thus, DCs, MDSCs, and circulating 
fibrocytes catabolizing Trp and Arg mediate tolerogenic processes in the TME. Collectively, 
these inflammatory cells contribute to barriers to natural and therapy-induced anti-tumour 
immunity, even if tumour cells themselves do not catabolize Trp or Arg. 
[H1] DNA sensing and Trp catabolism 
[H2] DNA from dying cells is a potent immune tolerogen  
Elevated Trp and Arg catabolism are common features of the TME in humans and mice but 
mechanisms linking tumour growth to increased Trp and Arg catabolism are poorly understood. 
Inflammatory pathways are strong candidates, as inflammatory cytokines stimulate IDO1, ARG 
and iNOS expression (Fig. 2). Moreover, some DCs in mice and humans express IDO in 
response to IFNs and suppress T cell responses 57,58,65. Further hints emerged from studies on 
immune responses to DNA nanoparticles and apoptotic (dying) cells in mice 66-70. These 
treatments induced robust IDO1-dependent tolerogenic responses that alleviated autoimmune 
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diseases and, in the case of apoptotic cells, protected skin allografts. Notably, in each case 
tolerogenic responses to DNA nanoparticles and apoptotic cells were STING dependent.  
[H2] DNA from dying tumour cells is sensed to activate STING and induce Trp catabolism 
Subcutaneous LLC tumour cell engraftment led to rapid and sustained elevation of IDO activity 
in tumour lesions and TDLN DCs via STING-dependent induction of IFNαβ signaling but not 
IFNγ signaling 22. Ablating cGAS attenuated IDO induction in some but not all mice, suggesting 
that other cytosolic DNA sensors that activate STING might compensate for loss of cGAS 
functions. Consistent with these findings, STING was required for optimal LLC tumour growth in 
dermal and lung sites, phenocopying requirements for IDO1 to promote optimal LLC growth. 
STING was also required to induce TDLN IDO activity during EL4 thymoma growth in mice, 
though STING ablation did not reduce IDO activity in EL4 lesions because tumour cells 
expressed IDO constitutively. B16 melanomas did not induce IDO activity in TDLNs 22; a 
surprising outcome in light of previous reports identifying DCs expressing IDO in TDLNs from 
mice bearing B16 tumours 56. However, in earlier studies IDO activity in TDLNs was not 
assessed directly and mice harboured cohorts of T cells specific for ovalbumin (OVA) expressed 
by B16 tumour cells. The presence of tumour-specific T cells can provide additional signals (e.g. 
IFNγ, CTLA4, PD-1) that induce and sustain IDO activity in DCs 71,72. Thus, DNA sensors 
induced IDO in some but not all mouse tumour models. Impaired STING signaling is common in 
many human cancers and cell lines and defective STING signaling might attenuate immune 
surveillance to promote tumourigenesis 73. However, this study did not address if DNA sensors 
induced IDO or if impaired STING signaling correlated with reduced IDO activity.  
[H2] Elevated tumour immunogenicity attenuates tolerogenic responses to DNA  
It is unclear why distinct requirements for DNA sensing to induce IDO manifest in different 
tumour models. One clue emerged from use of LLC tumour cells with elevated immunogenicity 
due to induced expression of neo-antigens. While parental LLC cells induced IDO to promote 
tumour growth, LLC cells expressing defined neo-antigens did not induce IDO in TDLNs, and 
STING signaling either had no effect on tumour growth or attenuated growth of tumours 
expressing neo-antigens 22. These outcomes suggest that increased potency of T cell 
responses to tumour antigens attenuated tolerogenic responses to DNA. As IDO was induced 
one day after tumour cell engraftment it is unclear how T cell responses could influence this 
rapid innate immune response to dying tumour cells. This point notwithstanding, elevated 
tumour immunogenicity clearly skews STING-dependent immune responses to DNA towards 
inhibition of tumour growth.  
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[H2]  Cell death influences immune balance in the TME  
Other potential factors that could influence immune responses to DNA during tumourigenesis 
include differential rates and modes of tumour cell death, DNA release, uptake or sensing of 
DNA by cells in the TME, or redundant requirements for IDO to promote tumour outgrowth. 
Studies on DNA sensing by mouse bone-marrow derived macrophages (BMDMs) underscore 
the ability of DNA to drive immune responses in opposing directions. While phagocytic BMDMs 
that ingested dying tumour cells sensed DNA to activate STING and trigger production of pro-
inflammatory cytokines 74, BMDMs that ingested apoptotic thymocytes sensed DNA via TLR9, a 
microbial and mitochondrial DNA sensor, to induce potent tolerogenic responses 75. Such 
diametric immune responses to DNA emphasize the need to better understand how distinct cell 
types in the TME sense DNA to enhance Trp catabolism and to optimise the use of IDO 
inhibitors to improve clinical responses to DNA-damaging chemotherapies or radiotherapies. 
Similar considerations may apply to other DAMPs that promote innate immunity. In particular, 
DAMPs that stimulate IFNαβ production may induce IDO1 activity downstream, though other 
DAMPs that induce IFNγ, IL-10 or TGFβ production could also enhance Trp and/or Arg 
catabolism 30,76. Collectively, these observations underscore the critical role of DNA and other 
DAMP sensors that activate inflammatory signaling pathways and influence immune balance in 
the developing TME. Moreover, recognition that DNA could promote tolerogenic or 
immunogenic responses in the TME has implications for cancer therapies using STING 
agonists.  
[H1] Roles of Trp catabolites  
Some Trp catabolites made downstream of IDO suppress immunity and other Trp catabolites 
are neurotoxic (Fig. 3). Thus, elevated Trp catabolism could not only attenuate anti-tumour 
immunity but also might cause undesirable neurologic changes during cancer development or 
promote neurotoxicities in response to cancer treatment.  
[H2] T cell suppression by Trp catabolites  
Kyn, which is exported by many cells expressing IDO, and its downstream catabolite KA are 
natural aryl hydrocarbon receptor (AHR) agonists, though KA is more effective than Kyn in 
activating AHR 77. AHR signaling regulates immunity and induces some DCs to express IDO 77-
81. Thus, Kyn and KA might amplify IDO activity via AHR signaling and promote tolerogenic 
processes in the TME, a paradigm supported by a study on human cancers expressing IDO 82. 
AHR signaling has multiple links with cancer, including regulation of oncogene expression, 
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angiogenesis, cell survival, as well as effects on immune cell functions 83. One study showed 
that the IDO pathway inhibitor D-1MT stimulated immune responses via an AHR-dependent 
mechanism in mesenchymal stem cells (MSCs) 84, suggesting that the anti-tumour effects of D-
1MT may in part depend on AHR activation in the TME, as well as IDO pathway modulation. 
The interface between Trp catabolism and AHR signaling provides numerous opportunities to 
modify the TME for clinical benefit, though the central role of AHR signaling in toxic responses 
to xenobiotic compounds such as dioxin, a synthetic AHR agonist, may be a limiting factor 85. 
Downstream of Kyn, 3-hydroxykynurenine (3HK) and 3-hydroxyanthranilic acid (HAA) are also 
immune suppressive. HAA inhibited pyruvate dehydrogenase kinase (PDK1) and NF-κB 
activation to block T cell proliferation, promote T cell apoptosis and activate Tregs, though how 
T cells and Tregs sensed HAA is unclear 86,87. These studies were not performed in cancer 
models and it is not known if 3HK and HAA condition the TME to promote tumour growth and if 
so, via which mechanisms. A recent study revealed a metabolic link between Trp catabolism 
and tetrahydrobiopterin (BH4) synthesis in T cells, as the Trp catabolite xanthurenic acid (XA) 
inhibited BH4 synthesis required to generate effector T cells 88. BH4 supplementation overcame 
XA-mediated suppression to boost anti-tumour immunity in mice, suggesting that IDO activity in 
the TME might block BH4 synthesis in T cells to attenuate anti-tumour immunity.   
The previous points raise a key issue, as TME cells express enzymes that further degrade 
specific Trp catabolites, making it difficult to ascertain which Trp catabolites mediate specific 
biological effects that impact tumour development, therapy or associated comorbidities. For 
example IFNγ induced human glioma cells to up-regulate IDO1, IDO2 and other genes encoding 
enzymes in the pathway (KMO, KYNU) but down-regulated others (ACMSD, KATII) 89. In this 
study, Kyn:Trp ratios were elevated in serum samples from glioma patients (consistent with 
elevated IDO activity) but KA, QA and PA levels were all reduced, relative to healthy individuals. 
These observations implicate Trp catabolism in glioma pathogenesis but also reveal the 
difficulty of correlating data on gene expression in tumour cell lines with metabolic effects 
caused by Trp catabolism in cancer patients. Another study in glioma patients showed that QA 
from brain microglial cells was converted via QPRT expressed in glioma cells into the oxidized 
form of nicotinamide adenine dinucleotide (NAD+), which inhibits apoptosis and increases 
resistance to oxidative stress and might contribute to glioma survival via these processes 90. 
Moreover, chemotherapy and radiotherapy enhanced QPRT expression by glioma cells, which 
might reinforce glioma cell protection in response to these therapies. Meta-analyses of public 
databases using an online tool (http://kmplot.com/analysis/index) of genes encoding specific 
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enzymes in the Trp catabolism pathway reveals several positive and negative correlations with 
cancer patient survival, though no uniform picture emerges that applies to multiple cancers. 
Clearly, elevated Trp catabolism impacts tumour growth, anti-tumour immunity and therapeutic 
responses in complex ways and improved methods to assess metabolic flux downstream of IDO 
are needed to understand how Trp catabolism mediates immune suppression and other 
processes relevant to cancer. Delivering recombinant enzymes that function downstream of IDO 
to reduce levels of immune suppressive Trp catabolites in the TME is a potential strategy to 
improve anti-tumour immunity. For example, administering recombinant, pegylated 
kynureninase (KYNU) to reduce Kyn levels in the TM attenuated immune suppression and 
promoted more effective tumour control in several mouse models when combined with immune 
checkpoint inhibitors or a cancer vaccine 91. Lower Kyn levels may be beneficial because Kyn 
(and/or downstream catabolites) mediate immune suppression and neuro-toxicity, though it may 
prove more challenging to reduce Kyn levels to levels that promote clinical responses in 
patients.  
[H2] Elevated Trp catabolism and cancer comorbidities  
 As in other chronic inflammatory syndromes, many cancer patients suffer chronic pain, 
depression, behavioural disorders and fatigue, and some cancer treatments exacerbate these 
comorbidities 92. Elevated Trp catabolism in the TME might contribute to these neurologic 
comorbidities, as some Trp catabolites are neuroactive (Fig. 3). Targeting specific enzymes 
might help alleviate comorbidities associated with some cancers and cancer treatments such as 
chronic pain and depression. Trp is the obligate substrate for 5HT synthesis and 5HT is an IDO 
substrate. Hence, sustained Trp catabolism reduces 5HT levels by removing Trp and degrading 
5HT with consequent negative impacts on mood and behavior 93. Moreover, targeting Trp 
catabolism to treat neurologic dysfunction in cancer patients might also help treat tumours, as 
many cancer cells and cell lines express 5HT receptors and 5HT signaling impacts tumour 
growth, metastasis and angiogenesis 94,95. 
Elevated Trp catabolism during chronic inflammation in cancer and other conditions may 
cause neurologic dysfunction due to sustained production of neuroactive Trp catabolites 96,97. 
QA and KA potentiate and antagonize, respectively, N-methyl-D-aspartate (NMDA) receptor 
signaling in neurons. In mice, genetic ablation of IDO1 prevented increase in mechanical 
nociception caused by chronic inflammation in models of LPS-induced arthritis and virus 
infections, while Kyn enhanced mechanical nociception in mice lacking IDO1 genes 96,97. Thus, 
elevated Trp catabolism in the TME might impact neurologic functions adversely before and 
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after clinical presentation of cancer, and therapy could alleviate or potentiate these effects 98. 
Strategies to manipulate Trp catabolites, especially in the central nervous system, might reduce 
these comorbidities in cancer patients. However, fatigue and pain were common adverse effects 
observed in a phase I trial with the IDO inhibitor Epacadostat, though it is unclear how effective 
this drug was in reducing Kyn levels, as it has a relatively short half life (2-4hrs) 99. 
[H1] Trp and Arg catabolism in therapy. 
The IDO pathway is an attractive target for intervention, as it affects multiple downstream 
pathways controlling cell growth, function and viability (Fig. 2). Recent reviews provide detailed 
discussion of IDO inhibitors in clinical development 36,100. Here we offer a brief summary of 
efforts to target IDO and TDO pathways with small molecule inhibitors focusing on the 
compounds most studied in the clinic. To aid discussion, Table 1 lists all compounds currently 
under investigation as potential IDO or IDO pathway inhibitor drugs to enhance immunologic 
responses to cancer.  
[H2] STING agonists and Trp catabolism in cancer therapy  
High IFNα and IFNβ  expression in tumour lesions correlates with spontaneous T cell priming 
by developing tumours 101. In immunogenic tumour models such as B16 melanoma expressing 
a neo-antigen (B16.SIY) this correlation occurs because DNA sensors activate STING-
dependent IFNα and IFNβ signaling to enhance antigen cross-presentation by CD8+ DCs, which 
primes robust anti-tumour immunity mediated by CD8+ T cells 102,103. These observations led to 
studies using synthetic cyclic dinucleotides (CDNs) that bind and activate STING as anti-cancer 
therapeutics. Intra-tumoural injection of CDNs induced tumour regression and systemic anti-
tumour immunity in mouse models of melanoma, colon and breast cancer 104,105. However, half 
of the mice failed to respond to CDN treatment and eventually succumbed to tumour growth. In 
addition, therapeutic responses were only partially dependent on IFNαβ signaling suggesting 
that other pro-inflammatory pathways might also promote immunogenic responses to CDNs. 
Though the anti-tumour effects of CDNs were not influenced by tumour immunogenicity, the 
requirement for STING to retard tumour growth manifested only if high numbers of B16.SIY cells 
were implanted 22,102,104. This suggests that tumour burden and immunogenicity might impact 
how STING signaling influences immune balance in the TME. Studies in the LLC model support 
this notion, as parental LLC tumours grew slower and LLC cells expressing neo-antigens grew 
faster in STING-deficient mice 22. Thus, CDN treatments might control highly immunogenic 
(“hot”) tumours more effectively because immune checkpoints that regulate anti-tumour 
immunity are less potent in these settings. How CDNs were administered to mice was also 
 15 
critical, as systemic CDN administration induced IDO activity in many mouse tissues; indeed, 
systemic CDN administration is an effective treatment to alleviate autoimmune arthritis and 
encephalitis in mice via IDO 70,106. These issues are clinically important because effective cancer 
immunotherapy must shift immune balance in the TME in favour of sustained dominance of 
immunogenic processes by disrupting established tolerogenic processes and – equally 
important – preventing subsequent re-emergence of tolerogenic processes after therapy (Fig. 
1).  
[H2] Immune balance and adverse responses to therapy  
The paradigm that effective cancer immunotherapy must reorient the immune balance in the 
TME raises several concerns. First, immunotherapy might shift immune balance too far, eliciting 
adverse toxicities due to enhanced immunity such as autoimmunity, a toxicity that manifests in 
some patients after immune checkpoint therapy 107,108. Exacerbation of pre-existing autoimmune 
diseases after checkpoint immune therapy has also been reported 109,110. Second, 
chemotherapy, radiotherapy and STING agonist treatments might stimulate tolerogenic 
responses that attenuate desired immunogenic responses. Notably, the efficacy of cytotoxic 
drugs is enhanced by IDO enzyme blockade in mice 20,21,111, perhaps via STING agonism 105. 
Poor clinical responses to some TLR ligands and tumour vaccines might arise in part because 
increased IDO activity dampens the innate immune adjuvant effects of these treatments 112,113. 
Similarly, IFNs might have limited efficacy as cancer therapies and in some cases enhanced 
tumour aggression, promoted metastasis and induced significant adverse toxicities, perhaps in 
part because they induced IDO, which attenuated clinical benefit 114-116. Lastly, neurologic co-
morbidities associated with some cancers (e.g. pain, altered behaviour, fatigue) and many 
cancer therapies (e.g. neuropathy, chemobrain), might be  linked mechanistically to elevated 
Trp catabolism, which can generate neurotoxic catabolites (Fig. 3). These considerations 
suggest that combining STING agonists with IDO inhibitors might be more effective and less 
toxic than monotherapies using one drug type. Moreover, this drug combination might be a 
more potent immunometabolic adjuvant to enhance anti-tumour responses than traditional 
cytotoxic therapies or immunotherapy (e.g. PD-1 or PD-L1 checkpoint inhibitors), even when 
these latter treatments are combined with IDO inhibitors.  
[H2] Cancer therapies targeting Trp catabolism 
The two most advanced drugs in development are indoximod and epacadostat (also known as 
D-1MT and INCB024360, respectively). Preliminary reports from meeting abstracts relating to 
other drugs being tested in ongoing clinical trials, include the IDO1 and TDO2 inhibitor 
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navoximod (NLG919), which is ~10-fold more selective as an IDO1 than TDO inhibitor 117,118, the 
selective IDO1 inhibitor BMS-986205 119, the IDO1 and TDO2 inhibitor PF-06840003 120, the 
IDO1 inhibitor KHK2455 121, and the D-1MT pro-drug NLG-802 122, the IDO1 inhibitor 
LY3381916, and the IDO1 and TDO2 inhibitor SHR9146. As a class, these drugs exhibit little 
efficacy as single agents and toxicity is limited and manageable. Combination drug trial designs 
are being evaluated given the strong rationale for using IDO inhibitors as immunometabolic 
adjuvants to enhance the efficacy of cytotoxic chemotherapy, radiotherapy and 
immunotherapies. 
To date, clinical evaluation of IDO inhibitors for cancer treatment has been driven largely by 
intense interest in identifying agents that improve the efficacy of immune checkpoint therapies, 
in particular anti-PD1 therapy. However, potent effects in preclinical tumour models were 
observed when IDO inhibitors were combined with ‘immunogenic’ cytotoxic chemotherapy 20. 
The rationale for combination immunotherapy is based on the potential for multiple immune 
checkpoints to be active at clinical presentation, and/or to suppress compensatory responses to 
monotherapies targeting a single checkpoint or conventional cytotoxic therapies 123,124. In 
addition, evidence from preclinical models shows that IDO inhibitors can enhance immune 
checkpoint therapy 125-127. Encouraging but preliminary Phase 1/2 data have emerged from 
studies combining PD1 or PDL1 pathway-inhibitors with: D-1MT for advanced melanoma 128-130; 
epacadostat for urothelial carcinoma 131, renal cell carcinoma 132, non-small cell lung cancer 
(NSCLC) 133, squamous cell carcinoma of the head and neck 134; BMS-986205 for various 
advanced cancers 119; and navoximod for advanced solid tumours (NCT02471846) 135. 
However, data from the first Phase 3 trial (ECHO-301) reported for anti-PD1 and epacadostat in 
metastatic melanoma revealed that epacadostat did not enhance therapeutic responses to PD-1 
blockade 136. Notwithstanding criticism of this Phase 3 trial 7 and promising outcomes in early 
phase trials 6, the disappointing outcome emphasizes the need for more biomarker analyses 
and improved mechanistic understanding of how T cell and metabolic immune checkpoints 
interact and compensate for each other during therapy.  
[H2] Cytotoxic chemotherapies and targeting Trp catabolism 
Many cytotoxic chemotherapies are ‘immunogenic’ and can enhance immune responses 137. 
As noted above, IDO inhibitors synergize powerfully with ‘immunogenic’ chemotherapy and 
enhance the efficacy of radiotherapy 20,21,138. Clinical regimens of immunochemotherapy or 
immunoradiotherapy that include IDO inhibitors are appealing in principle, to take advantage of 
synchronous tumour cell death and tumour-related antigen release 139 that may enhance 
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antigen cross-presentation by APCs to stimulate effector T cells in the TME. In a Phase 1 study 
in metastatic breast cancer patients, the combination of D-1MT and docetaxel was well tolerated 
with no additive toxicity and an objective response rate of 18% (4/22 with partial responses) and 
an additional 45% (10/22) achieving at least transient stable disease 140; however, results from a 
follow-on randomized, placebo-controlled phase 2 trial are not yet available. Other early-phase 
combination drug trials are studying D-1MT in combination with: gemcitabine and nab-paclitaxel 
for metastatic pancreatic cancer 141,142; temozolomide with or without bevacizumab for 
temozolomide-refractory glioblastoma 130; and cytarabine and idarubicin for newly diagnosed 
AML 143. Additionally, a dedicated Phase 1 paediatric trial combining D-1MT with temozolomide 
for recurrent brain cancer or newly diagnosed diffuse intrinsic pontine glioma patients is ongoing 
144,145. To date, all these combinations have been well tolerated with little indication of any 
overlapping toxicity with chemotherapy, though it is important to emphasize the preliminary 
nature of these early reports.  
[H2] Radiation therapy and targeting Trp catabolism 
Like many chemotherapies, radiation treatments induce a highly inflammatory milieu in 
targeted tissues in preclinical studies 146, including expression of IFNs and other mediators that 
induce IDO. If potent cytotoxic and immunogenic effects of radiation are combined with IDO 
inhibitor therapy to enlist targeted immune responses to residual tumour cells, it may be 
possible to craft less toxic radiation strategies that retain effectiveness with reduced off-target 
radiation exposure 144. A recent preclinical study encourages immunoradiotherapy strategies 
incorporating anti-PD-1 as well as IDO inhibition 147. Another potential benefit of combining 
immunotherapy with radiation is the possibility of achieving abscopal responses, where local 
radiation delivered to one tumour may lead to regression in a distant tumour outside the 
radiation field 148-151. Abscopal responses to radiotherapy may be immune-mediated and may 
reflect high-grade immune priming. To date, few clinical studies have combined IDO-inhibitor 
therapy (D-1MT) with radiosurgery for adult refractory glioblastoma 130 and pediatric recurrent 
brain cancers or newly diagnosed pontine glioma 144,145. Preliminary results indicate that this 
combination was well tolerated when followed by cyclic immuno-chemotherapy using D-1MT 
plus temozolomide. Using IDO inhibitors as immunometabolic adjuvants to radiological and 
cytotoxic treatment modalities may enhance immune responsiveness with little added toxicity. 
[H2] Trp catabolism and cancer biomarkers  
Recent clinical findings suggest that biomarker analyses will be critical to determine how IDO 
inhibitors can be used most effectively. Excitement in the field of cancer immunotherapy has 
encouraged aggressive entry to large (Phase 3) trials that, in retrospect appears premature 7. 
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For example, tumour lesions often generate nitric oxide, (possibly due to iNOS activity), which 
inhibits IDO activity 28, emphasizing the critical importance of measuring IDO activity. However, 
few studies have evaluated IDO activity before and after therapy but instead rely on assessing 
IDO gene or protein expression. Systemic IDO activity was evaluated by assessing levels of Trp 
and Kyn in serum samples from patients with NSCLC before, during and after patients received 
radiotherapy 152. While many (65%) patients with low serum IDO activity before and after 
radiotherapy were alive 10 years after radiotherapy, all NSCLC patients with relatively high 
serum IDO activity succumbed within 3 years. Furthermore, IDO activity was reduced during 
radiotherapy in most NSCLC patients but IDO activity levels increased after radiotherapy in 
some patients. These findings reinforce the notion that IDO activity contributes to immune 
checkpoints, show that radiotherapy disrupts this barrier to clinical responses (albeit only 
transiently in some cases), and suggest that serum Kyn levels  may be an informative biomarker 
of clinical responsiveness to radiotherapy in some cancer patients.  
[H1] Conclusions and Future Directions  
Extensive evidence supports the notion that elevated Trp and Arg catabolism contributes to 
immune regulation that promotes tumour growth and therapy resistance. Targeting these 
biochemical pathways in cancer patients offers promise and many drugs are under development 
with this goal in mind. However, setbacks in a recent clinical trial reveal the need for more 
research to better understand how changes in amino acid transporters, sensors and catabolism 
impact immune responses in the TME. Biochemical changes associated with increased Trp and 
Arg catabolism have many effects on the function and viability of tumour, stromal and immune 
cells in the TME. Other outstanding questions are how Trp and Arg catabolism contributes to 
other immune regulatory mechanisms in the TME and how immune checkpoint blockade 
impacts Trp and Arg catabolism. There are also clear unmet needs to identify biomarkers of the 
potency of amino acid catabolism in cancer patients as ways to identify patients likely to benefit 
from treatments targeting amino acid catabolism. In this arena, biomarkers to inform patient 
recruitment to trials of IDO inhibitors are needed, as well as to inform how best to use DNA 
damaging therapy plus PD1 inhibitors (or other immunotherapy), as an immunometabolic 
adjuvant. Given the current focus on enhancing anti-tumour immunity, there is enormous 
interest in gaining more understanding of how chronic inflammation associated with 
tumourigenesis stimulates local Trp and Arg catabolism that regulates immune responses. 
Furthermore, it will be important to identify innate and adaptive immune biomarkers for the 
stimulation of pathogenic amino acid Trp and Arg catabolism during tumourigenesis as potential 
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clues to the underlying fundamental processes of immune escape that promote cancer 
development or relapse after therapy.  
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Figure Legends: 
Figure 1. Inflammatory and immunologic processes during tumourigenesis. (a) Local 
immune surveillance and anti-tumour immunity prevents pre-malignant lesions from forming 
tumours in most people (green boxes). In some people, local inflammatory processes 
associated with pre-malignant lesions promote immune regulatory (tolerogenic) processes that 
overcome immune surveillance and establish robust immune checkpoints at clinical 
presentation of cancer (purple boxes). Increasing rates of cell death and consequent release of 
damage-associated molecular patterns (DAMPs) such as cellular DNA are common features of 
developing tumour lesions, which may contribute to dominance of tolerogenic processes that 
promote tumour development. (b) Changes in the inflammatory and immunologic status of 
primary tumour lesions are accompanied by parallel changes in tumour-draining lymph nodes 
(TDLNs) that promote development of regulatory antigen presenting cells (APCs) and Tregs, 
which suppress generation of stimulatory APCs and helper and effector T cells. Elevated Trp 
and Arg catabolism may manifest in primary tumour lesions, in TDLNs or in both. Hence, 
effective cancer therapy must disrupt immune checkpoints to allow anti-tumour immunity to 
manifest and must also prevent re-emergence of tolerogenic processes following therapy that 
may cause tumour relapse.  
 
Figure 2. Inflammatory processes stimulate Trp and Arg catabolism in the TME. 
Inflammation increases local cell stress and death rates. DAMPs released by stressed and 
dying cells excite DAMP sensors (such as TLRs, NLRs and cGAS–STING) that activate 
immune cells directly or indirectly. Activated immune cells may acquire regulatory or stimulatory 
functions (purple and green coloured cells, respectively). Interferons (IFNs) have prominent 
roles in activating immune cells and are also released by activated innate and adaptive immune 
cells. IFNs and other inflammatory cytokines also stimulate expression of genes encoding 
enzymes that promote Trp and Arg catabolism, including IDO, ARG1 and iNOS (shown in blue). 
TDO is not IFN responsive but is induced by dietary stress and glucocorticoids. Sustained Trp 
and Arg catabolism suppresses local immune responses via mechanisms dependent on GCN2, 
mTOR or AHR that impact tumour growth and therapy, and may also contribute to comorbidities 
commonly associated with cancer. 
 
Figure 3. Immunologic and neurologic consequences of Trp catabolism relevant to 
cancer. Cells expressing IDO or TDO generate downstream Trp catabolites that impact 
immunologic or neurologic processes. Kynurenine (Kyn), 3-hydroxykynurenine (3HK) and 3-
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hydroxyanthranilic acid (HAA) suppress immune responses, while xanthurenic acid (XA) inhibits 
BH4 synthesis required to generate effector T cells. Several Trp catabolites generated 
downstream, kynurenic acid (KA), quinolinic acid (QA) and picolinic acid (PA), are neuroactive. 
Trp is also the obligate substrate for synthesis of serotonin (also known as 5-hydroxytryptamine 
(5HT)) and melatonin, which promote positive neurologic behaviours. Sustained Trp catabolism 
may drive neurologic comorbidities commonly associated with cancer development or linked to 
some cancer therapies. Cells expressing iNOS or ARG1 catabolize Arg to generate nitric oxide 
and polyamines, which impact vascular, immunologic and other physiologic processes. Other 
Abbreviations: Tryptophan hydrolase (TPH), kynurenine monooxygenase (KMO), anthranilic 
acid (AA), kynureninase (KYNU), kynurenine aminotransferase (KAT), 3-hydroxyanthranic acid 
3,4-dioxygenase (HAAO), 2-Amino-3-carboxymuconic acid-6-semialdehyde (ACMSD), 
quinolinate phosphoribosyl transferase (QPRT), N-methyl-D-aspartate receptor (NMDA-R), 
nicotinamide adenine dinucleotide (NAD). Dashed arrows indicate multiple enzyme steps. 
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Table 1. IDO1 inhibitors under preclinical and clinical evaluation. Evaluation of multiple 
IDO1 inhibitors at a clinical stage of development has been delayed due to negative results 
obtained in the Phase 3 trial KEYNOTE-252/ECHO-301 (NCT02752074), a combination of the 
field's lead compound epacadostat with the anti-PD1 immune checkpoint therapy 
pembrolizumab widely expected to be efficacious108. [AU: As tables cannot include legends 
please move this information to the main text, You can add a footnote stating development has 
been delayed/terminated. Also, should ref 112 be cited instead of 108?] 
 
 
Drug name(s) Structure Mechanis
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Kinetics 
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D-1MT (also known as 
Indoximod and NLG-
8186) [Au:OK?]  
 
Stimulates 
mTORC1 
downstream 
of 
IDO1/TDO 
 
NA NA Non-selective NewLink 
 
2008 Phase 3† 
Epacadostat 
(also known as 
INCB024360) 
 
Catalytic  
inhibitor 
Tryptophan  
competitive 
 
12 nM 
>100-fold Incyte 2012 Phase 3* 
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BMS-986205 
(also known as F001287) 
 
Apoptosis 
[Au:OK?]  
inhibitor 
Irreversible 2 nM >100-fold BMS 
Flexus 
 
2015 
Phase 3† 
Navoximod 
(also known as NLG-919) 
 
Catalytic  
inhibitor 
Tryptophan  
non-competitive 
75 nM 10-20 fold NewLink 
 
2015 Phase 1B/2 
PF-06840003 
 
Catalytic 
inhibitor 
Tryptophan  
non-competitive 
1100 nM >100-fold Pfizer 
iTeos 
2016 Phase 1 
IOM2983 Unknown 
Patent Published [Au: If 
possible, please cite the 
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Unknown Unknown Unknown >100-fold Merck 
IO-Met 
NA Preclinical 
 
RG-70099 
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Patent Published[Au: If 
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Unknown Unknown Unknown ~5-fold Roche 
Curadev 
 
NA Preclinical 
 
*Development in combination with pembrolizumab for melanoma terminated due to negative results 
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†Phase 3 trial delayed following negative results obtained from KEYNOTE-252/ECHO-301 trial of 
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This Review discusses how increased catabolism of the amino acids tryptophan and arginine in 
the tumour microenvironment contributes to inflammatory processes that promote 
tumourigenesis, impede immune responses to therapy and might promote neurologic 
comorbidities associated with cancer.  
 
 
